| Autor: |
Tran JC, Hunsaker T, Bell C; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Ma TP, Chan E, Larrocha PS, Homyk K, Liu L, La H, Mao J, de la Cruz CC, Yu K, Beresini M, Forrest WF, Xiao Y, Jang A; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Samus N; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Stesco ND; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Mentinova M; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Parent S; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Pottiez G; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Schirm M; CellCarta, Montreal, Quebec H2X 3Y7, Canada., Purkey HE, Liu Y, Merchant M |
| Abstrakt: |
The growing opportunities recognized for covalent drug inhibitors, like KRAS G12C inhibitors, are driving the need for mass spectrometry methods that can quickly and robustly measure therapeutic drug activity in vivo for drug discovery research and development. Effective front-end sample preparation is critical for proteins extracted from tumors but is generally labor intensive and impractical for large sample numbers typical in pharmacodynamic (PD) studies. Herein, we describe an automated and integrated sample preparation method for the measurement of activity levels of KRAS G12C drug inhibitor alkylation from complex tumor samples involving high throughput detergent removal and preconcentration followed by quantitation using mass spectrometry. We introduce a robust assay with an average intra-assay coefficient of variation (CV) of 4% and an interassay CV of 6% obtained from seven studies, enabling us to understand the relationship between KRAS G12C target occupancy and the therapeutic PD effect from mouse tumor samples. Further, the data demonstrated that the drug candidate GDC-6036, a KRAS G12C covalent inhibitor, shows dose-dependent target inhibition (KRAS G12C alkylation) and MAPK pathway inhibition, which correlate with high antitumor potency in the MIA PaCa-2 pancreatic xenograft model. |
